Related Experiment Video
Updated: Jan 28, 2026

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer
Published on: June 13, 2019
Abstract:
Niraparib showed promising signs of efficacy in the phase II GALAHAD trial of men with advanced prostate cancer whose tumors harbor mutations in the DNA damage-response pathway, especially among patients with gene defects in BRCA1 or BRCA2.
Insights
Niraparib demonstrates efficacy in advanced prostate cancer patients with DNA damage-response pathway mutations. The drug is particularly effective in men with BRCA1 or BRCA2 gene defects.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- The GALAHAD trial investigated niraparib in men with advanced prostate cancer.
- Patients had tumors with mutations in the DNA damage-response (DDR) pathway.
Discussion:
- Niraparib, a PARP inhibitor, targets DNA repair mechanisms.
- Tumor mutations in DDR genes, including BRCA1/2, confer sensitivity to PARP inhibitors.
Key Insights:
- Niraparib showed promising efficacy in this patient population.
- Efficacy was most pronounced in patients with BRCA1 or BRCA2 gene mutations.
Outlook:
- Further research may establish niraparib as a treatment option for specific prostate cancer subtypes.
- Genomic profiling can identify patients likely to benefit from niraparib therapy.
More Related Videos
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Mutations in Microorganisms
Point and Frameshift Mutations

